GLP-1受体激动剂与颅内动脉瘤患者蛛网膜下腔出血风险降低相关
该回顾性队列研究基于TriNetX全球数据库(2010年1月至2025年1月),比较合并2型糖尿病的未破裂颅内动脉瘤患者中接受与未接受GLP-1受体激动剂者的结局。经倾向评分1:1匹配后每组2275例,GLP-1RA使用与5年非创伤性蛛网膜下腔出血风险(HR 0.66,95%CI 0.50-0.87)及全因死亡风险(HR 0.63,95%CI 0.52-0.76)降低相关,尚需前瞻性试验证实。
要点
- 合并2型糖尿病的未破裂颅内动脉瘤患者使用GLP-1RA与5年非创伤性SAH风险降低相关。
- 匹配后GLP-1RA组全因死亡风险亦降低,HR 0.63(95%CI 0.52-0.76)。
- 结果来自回顾性数据库分析,仅提示相关性,需前瞻性试验验证。
核心结论
- 在合并2型糖尿病的颅内动脉瘤患者中,GLP-1RA使用与5年非创伤性蛛网膜下腔出血及全因死亡风险降低相关,但需前瞻性试验确认。
研究设计与样本
- 回顾性队列研究,使用覆盖北美、南美、欧洲和亚洲90余家医疗机构的全球TriNetX数据库,数据时间为2010年1月至2025年1月。
- 另对无颅内动脉瘤治疗史者行匹配亚组分析,并进行伪造分析评估医疗资源利用偏倚。
主要发现
- 匹配后GLP-1RA使用与非创伤性SAH风险降低相关(HR 0.66,95%CI 0.50-0.87)。
- 匹配后GLP-1RA使用与全因死亡风险降低相关(HR 0.63,95%CI 0.52-0.76)。
- 未治疗患者匹配亚组中,非创伤性SAH(HR 0.68,95%CI 0.47-0.98)与全因死亡(HR 0.64,95%CI 0.53-0.77)风险同样降低。
- 伪造分析提示不存在适应证混杂与医疗可及性偏倚。
临床怎么用
- 对合并2型糖尿病的未破裂颅内动脉瘤患者,选择降糖药物时可考虑GLP-1RA的潜在获益,但不应仅据此改变动脉瘤管理决策。
- 该证据为回顾性观察性研究,不能确立因果关系,临床决策仍需结合个体风险评估。
局限性
- 为回顾性数据库队列研究,存在残余混杂可能,结论需前瞻性试验证实。
- 数据主要由美国机构贡献,外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The potential protective effect of GLP‑1RAs against nontraumatic subarachnoid hemorrhage (SAH) in individuals with intracranial aneurysms (IAs) remains unclear. Since GLP-1RAs (glucagon-like peptide-1 receptor agonists) have known anti-inflammatory and antihypertensive properties, we proposed to evaluate whether they reduce the risk of nontraumatic SAH in patients with IA with type 2 diabetes. METHODS: We conducted a retrospective cohort study using the global TriNetX database, which spans over 90 health care organizations across North America, South America, Europe, and Asia, with the majority of data contributed by the United States. Analysis included data from January 2010 to January 2025. Patients with unruptured IAs and type 2 diabetes who received GLP‑1RAs (n=2517) were compared with those who did not (n=23 431). Propensity score matching (1:1) was performed on 95 demographic and clinical variables, including smoking and hypertension. A subgroup and matched analysis excluded patients who had a history of IA treatment. The primary outcomes were nontraumatic SAH and all‑cause mortality over a 5‑year follow‑up period. Hazard ratios (HRs) and 95% CIs were calculated, and a falsification analysis was performed to evaluate whether patients taking GLP-1RAs were receiving more medical care. RESULTS: After matching, each cohort comprised 2275 patients. GLP‑1RA use was associated with a significantly lower rate of nontraumatic SAH (HR, 0.66 [95% CI, 0.50-0.87]) and all‑cause mortality (HR, 0.63 [95% CI, 0.52-0.76]). In the matched subgroup analysis of untreated patients, GLP‑1RA use was similarly associated with reduced risk of nontraumatic SAH (HR, 0.68 [95% CI, 0.47-0.98]) and all‑cause mortality (HR, 0.64 [95% CI, 0.53-0.77]). Falsification analysis confirmed the absence of confounding by indication and health care access bias. CONCLUSIONS: GLP‑1RAs have a potential role in mitigating nontraumatic SAH and improving survival among patients with IA with type 2 diabetes. Prospective trials are warranted to confirm these findings.
引用
- Feghali J, Ruchika F, Horowitz MA, et al. Glucagon-Like Peptide-1 Receptor Agonists and Decreased Subarachnoid Hemorrhage Risk in Patients With Intracranial Aneurysm. Stroke. 2026. PMID: 41492776. doi:10.1161/STROKEAHA.125.053599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。